News
-
Genelux Corporation Announces Early Results Of A Phase I/II Clinical Trial Of Virotherapeutic GL-ONC1 In Advanced Peritoneal Cavity Cancers
11/1/2012
Genelux Corporation, a clinical-stage biopharmaceutical company developing vaccinia virus based oncolytic cancer therapies and companion diagnostics, announced early results of the first patient cohort treated in a Phase I/II clinical trial with GL-ONC1, its leading virotherapeutic product candidate, in patients with advanced peritoneal cavity cancers. As presented at the 8thWorld Congress on Peritoneal Surface Malignancies in Berlin, Germany, GL-ONC1 was found to be clinically well tolerated when applied directly into the peritoneal cavity.
-
Dynavax To Initiate Phase 1 Studies For TLR-9 Agonist For Asthma
10/31/2012
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into Phase 1 clinical studies.
-
Results From Five Phase III Studies Presented For GSK’s Two Candidate Quadrivalent Influenza Vaccines
10/22/2012
GlaxoSmithKline plc (GSK) recently announced that results from five Phase III studies investigating its two candidate quadrivalent influenza vaccines (QIVs) were presented at the Influenza Vaccines for the World (IVW) congress in Valencia, Spain and the Infectious Diseases week (IDweek) congress in San Diego, USA in October.
-
Fab’entech Launches A Phase I Clinical Trial In Singapore For Its New Product Against H5N1 Avian Influenza
10/11/2012
Fab’entech, a French biopharmaceutical company specialized in developing specific polyclonal immunoglobulins against emerging infectious diseases announces that the company is launching its first clinical trial in humans for its product against the H5N1 Avian Influenza virus.
-
Aeras Signs Agreement With GSK To Jointly Advance TB Vaccine
10/10/2012
Aeras announces that it has signed an agreement with GlaxoSmithKline Vaccines, S.A. (GSK) to jointly advance the clinical development of an investigational tuberculosis (TB) vaccine containing GSK’s proprietary M72 antigen and AS01E adjuvant.
-
Novavax Initiates Phase 2 Clinical Trial Of RSV Vaccine Candidate
10/8/2012
Novavax, Inc. today announced that enrollment has begun in a Phase 2 dose-ranging clinical trial of its respiratory syncytial virus (RSV) vaccine candidate in women of childbearing age.
-
First Results From Phase 3 CANVAS Trial Show Canagliflozin As Add-on Therapy To Insulin Lowered Blood Sugar Levels In Patients With Type 2 Diabetes At An Elevated Risk For Cardiovascular Disease
10/2/2012
Janssen Research & Development, LLC (Janssen) today announced that use of the investigational medicine canagliflozin substantially lowered blood glucose levels when used as add-on therapy in patients on insulin therapy for type 2 diabetes and who are considered to be at greater risk for cardiovascular disease.
-
Advanced BioScience Laboratories Awards Avid Bioservices HIV Vaccine Development And Manufacturing Contract
9/27/2012
Avid Bioservices, a subsidiary of Peregrine Pharmaceuticals, Inc., today announced that it has been chosen by Advanced BioScience Laboratories, Inc. (ABL) to provide development and large-scale manufacturing services to support cGMP production of an HIV envelope protein, as a component of a preventive vaccine against HIV infection.
-
ViroPharma And Halozyme Provide Update On Clinical Development Of Subcutaneous Cinryze® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20)
9/21/2012
ViroPharma Incorporated (Nasdaq: VPHM) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced today that the U.S. Food & Drug Administration (FDA) has provided guidance enabling ViroPharma to resume clinical studies of the subcutaneous administration of Cinryze in combination with rHuPH20.
-
Sanofi Pasteur Announces Publication In The Lancet Of World's First Efficacy Results For Its Dengue Vaccine Candidate
9/11/2012
Sanofi Pasteur, the vaccines division of Sanofi, announced recently the online publication in The Lancet of clinical study results showing the ability of its vaccine candidate to protect against dengue fever caused by three dengue virus types. The results of the world’s first efficacy study confirm the excellent safety profile of Sanofi Pasteur’s dengue vaccine candidate.